Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

FDA Approves Bristol’s Opdivo With Chemotherapy for Lung Cancer

March 4, 2022, 10:49 PM

FDA approves Opdivo (nivolumab) with chemotherapy as neoadjuvant treatment for certain adults with resectable non-small cell lung cancer, Bristol Myers Squibb says.

  • Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer

NOTE

  • Bristol-Myers Squibb Co. fell 0.2% in postmarket trading to $69.25 as of 5:45 p.m. New York time
    • The average 12-month price target of $72.90 is 5.3% above the current price
    • 15 buys, 9 holds, 0 sells

To view the source of this information, click here

To contact the reporter on this story:
Jim Silver in New York at jsilver@bloomberg.net

To contact the ...